Wednesday - June 10, 2026
GSK: Blenrep Approved in China for Treatment of 2L+ Relapsed/refractory Multiple Myeloma
April 21, 2026
LONDON, England, April 21 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on April 20, 2026:

* * *

Blenrep (belantamab mafodotin) approved in China for treatment of 2L+ relapsed/refractory multiple myeloma

* Blenrep combination showed a 42% reduction in risk of death and nearly tripled median progression-free survival versus a daratumumab-based triplet/1,2

* As the only anti-BCMA approved in 2L+ . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products